WINTON GROUP Ltd Buys 79,222 Shares of Solventum Corporation $SOLV

WINTON GROUP Ltd lifted its holdings in Solventum Corporation (NYSE:SOLV) by 491.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 95,345 shares of the company’s stock after buying an additional 79,222 shares during the quarter. WINTON GROUP Ltd owned about 0.05% of Solventum worth $7,555,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Assetmark Inc. raised its holdings in shares of Solventum by 21.4% in the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after buying an additional 128 shares during the last quarter. Allworth Financial LP raised its holdings in shares of Solventum by 2.8% in the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after buying an additional 129 shares during the last quarter. Hilltop National Bank raised its holdings in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after buying an additional 129 shares during the last quarter. CIBC Private Wealth Group LLC raised its holdings in shares of Solventum by 0.5% in the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after buying an additional 134 shares during the last quarter. Finally, BOKF NA raised its holdings in shares of Solventum by 6.9% in the third quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after buying an additional 141 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SOLV. Piper Sandler cut their price target on Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a report on Friday, April 17th. UBS Group cut Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Thursday, May 14th. Wedbush initiated coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target for the company. KeyCorp lifted their price objective on Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Finally, BTIG Research reiterated a “buy” rating and issued a $89.00 price objective on shares of Solventum in a research report on Wednesday, May 6th. Eight research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Solventum currently has a consensus rating of “Moderate Buy” and an average target price of $84.25.

Insider Buying and Selling

In other news, Director Amy Mcbride Wendell acquired 1,475 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was purchased at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.24% of the stock is currently owned by insiders.

Solventum Price Performance

Shares of SOLV stock opened at $81.07 on Friday. The stock has a 50-day moving average price of $70.91 and a 200 day moving average price of $75.21. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The firm has a market cap of $14.04 billion, a price-to-earnings ratio of 9.93, a PEG ratio of 1.27 and a beta of 0.69. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $88.20.

Solventum (NYSE:SOLV) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. The firm had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The company’s revenue was down 3.0% on a year-over-year basis. During the same period last year, the company earned $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Research analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.